Thank you for a fantastic year and all your support!
Wishing you a Merry Christmas and a Happy New Year!
Across Markets…
The Australian sharemarket climbed to a six-week-high after broad gains on Tuesday, as momentum buying from investors extended ahead of the holidays.
The S&P/ASX 200 added 98.8 points, or 1.1 per cent, to 8795.7 in the fourth consecutive session of gains. The bourse has bounced 2.5 per cent since December 18. Over the year, it has risen nearly 8 per cent.
IG market analyst Tony Sycamore said the delayed start to this year’s “Santa rally” supports the view that the seasonal uplift is shifting. The Santa rally typically occurs between the last five trading days of the year and the first two days of the new year. “Assuming the month’s low at 8547.1 holds firm, this compressed volatility leaves plenty of room for the rally to extend towards our 8850 end-of-year target in early December.”
The Reserve Bank of Australia’s latest minutes failed to dampen investor optimism, despite revealing that policymakers weighed up the prospect of an interest rate rise in 2026. The minutes from the December meeting confirmed that the board discussed the potential need for further tightening in response to accelerating inflation. However, the central bank ultimately struck a cautious tone, concluding it would require a “little” more time.
On the ASX, all 11 sectors advanced, led by real estate thanks to an 8.3 per cent leap in Goodman Group to $31.63 after it signed a $14 billion European partnership to develop data centres in Frankfurt, Amsterdam and Paris.
Source: AFR
Who will take out line honours as the ASX biotech winner of 2025?
- In a tight race, drug developer Nyrada so far is this year’s star performer with almost an eightfold gain
- Diagnostic house Lumos and imagers Artrya and 4D Medical also have run a good race, with their US plans unfolding to script
- Nyrada chief James Bonnar says: “finally, biotech good news is being rewarded”
Despite the gloom enveloping the sector for most of the year, a cluster of ASX biotechs chalked up spectacular gains amid a steady flow of regulatory approvals, big-ticket distribution deals and successful trials.
Barring any protest siren or hidden winged keels producing a late upset, the low-key drug developer Nyrada (ASX:NYR) looks like taking out line honours as the best-performing ASX biotech winner of 2025.
As of last night’s close, Nyrada shares had soared 788% year to date.
Nyrada fended off point-of-care diagnostics innovator Lumos Diagnostics (ASX:LDX) , which saw a 685% surge on the back of a breakthrough US commercialisation deal.
In a tight race for third, heart diagnosis play Artrya is edging out lung-imaging house 4D Medical (ASX:4DX) for the bronze chalice.
The difference? 675% versus 660%, although at one stage 4D Medical’s shares were 1500% higher.
Nyrada CEO James Bonnar notes that since February 2024, the stock has climbed from two cents to as high as $1.05 in November – a sizzling 5100% increment
“We have had a good cadence of announcements,” Bonnar says.
“Finally, biotech good news is being rewarded”.
Source: Stockhead
Company: Locksley Resources Ltd (ASX:LKY)
Sector: REE & Antimony/Mining
Deal Type: Placement
Latest Entry Price: $0.04
Today’s Price Change: $0.195
Company: CuFe Ltd (ASX:CUF)
Sector: Copper/Mining
Deal Type: Placement
Latest Entry Price: $0.016 with 1:2 option, strike $0.025
Today’s Price Change: $0.033
Company: Tasman Resources Ltd (ASX:TAS)
Sector: Gold/Silver/Mining
Deal Type: Placement
Latest Entry Price: $0.0125 with 1:2 option, strike $0.02
Today’s Price Change: $0.019
Company: Tambourah Metals Ltd (ASX:TMB)
Sector: Gold/Mining
Deal Type: Placement
Latest Entry Price: $0.04
Today’s Price Change: $0.048
Company: Eclipse Metals Ltd (ASX:EPM)
Sector: REE
Deal Type: Placement
Latest Entry Price: $0.015
Today’s Price Change: $0.020
Company: Neuren Pharmaceuticals Ltd (ASX:NEU)
Sector: Biotech
Deal Type: On-market purchase
Latest Entry Price: $1.20 – $1.50
Today’s Price Change: $20.14
Company: Dimerix Ltd (ASX:DXB)
Sector: Biotech
Deal Type: Rights Issue
Raise Amount: $800,000
Latest Entry Price: $0.08 with 1:1 option, strike $0.126
Today’s Price Change: $0.625
Company: Noviqtech Ltd (ASX:NVQ)
Sector: Blockchain
Deal Type: Placement
Raise Amount: $1M
Latest Entry Price: $0.02 with 1:1 option $0.08 strike
Today’s Price Change: $0.021
Company: Critica Limited (ASX:CRI)
Sector: REE
Deal Type: Placement
Raise Amount: $1M
Latest Entry Price: $0.0075 with a 1:1 CRIO
Today’s Price Change: $0.026
Company: Patagonia Lithium (ASX:PL3)
Sector: Lithium
Deal Type: IPO
Raise Amount: $8.6M
Latest Entry Price: $0.09 with 1:2 PL3O
Today’s Price Change: $0.054
Company: WhiteHawk Ltd. (ASX:WHK)
Sector: Cybersecurity & AI
Deal Type: Placement
Raise Amount: $1.7M
Latest Entry Price: $0.01 with 1:3 option $0.02 strike
Today’s Price Change: $0.008
Company: Kalgoorlie Gold Mining Limited. (ASX:KAL)
Sector: Gold/Mining
Deal Type: Placement
Raise Amount: $2.3M
Latest Entry Price: $0.026 with 1:2 option $0.032 strike
Today’s Price Change: $0.046
If you would like more information on future Peak deals, please don’t hesitate to get in touch.
Peak accepts no responsibility for any views expressed and marketing material contained in this email except where the message specifically states otherwise and the sender is authorised to state them to be the views of Peak. Information provided in this email is general advise only and does take account your objectives, financial situation or needs. Before acting on any advice in this email, Peak recommends that you consider whether it is appropriate for your circumstances. If this email contains reference to any financial products, you should obtain the current Product Disclosure Statement (PDS) or other disclosure documents for the particular products and consider this information before making any decisions regarding the products. The Financial Services Guide (FSG) can be found at www.peakassetmanagement.com.au or by telephoning Peak on 1300 304 460
Comments are closed